Göttingen, Germany – In individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), uric acid (UA) metabolism might be involved in activation of the complement system and thus serve as a contributory factor in the disease course, according to findings from a retrospective study published in the International Journal of Molecular...
Latest News
PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...
Minnesota nice is being proven all over again. A young man from Africa says he is proof of that as doctors in St. Paul rebuild not only his face but his entire future. Even for skilled specialists, the surgical case on the table before them is a challenge. “It’s kind...
Orphan Therapeutics, LLC and Ikaria Holdings, Inc announced that the US Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing seeking marketing approval for Lucassin (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type-1. The filing was completed on May...
SHELTON, CT – NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted a “Rare...
Basel, Switzerland – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive...
Basel, Switzerland – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept). The Federal Circuit previously ruled against Sandoz in...
Los Angeles, Calif. – Acute lymphoblastic leukemia (ALL), the most common childhood cancer, especially affects children of Hispanic/Latino origin in the United States. They are 30-40% more likely to get ALL than non-Hispanic white children, but the exact genetic basis and cause of that increased risk are unknown. Now, a...
Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break—an occurrence that marks the first step in the development of human lymphoma. The study provides researchers with the clearest insight yet into why...
Los Angeles, Calif. – The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first-of-its-kind genetic therapy for glioblastoma, a severe form of brain cancer. The treatment would be the first gene therapy for glioblastoma to use a novel, more precise delivery...